Wintermute Biomedical Pty Ltd

Developing novel, safe, & effective #antimicrobials to combat #infectiousdiseases

Currently focused on a topical treatment for #shingles

[Wintermute Biomedical Pty Ltd @WintermuteBio]

Delighted to welcome Prof. Tony Cunningham, a world-renowned viral immunologist and #infectiousdiseases expert, to our clinical advisory board!

His expertise in #shingles and herpes vaccine development will support our Solexan™ pipeline.

Read more: https://t.co/R0zgeLYXD2

[Wintermute Biomedical Pty Ltd @WintermuteBio]

We are thrilled to share our recent collaboration with @fabian_kong to explore the utility of our #antimicrobial formulations against oral gonorrhoea!

[Fabian YS Kong (He/Him) @fabysk.bsky.social @fabian_kong]

I am very excited to work with @WintermuteBio to screen their fatty acid-based formulations. The goal? To develop a topical product such as a chewing gum to prevent oral gonorrhoea infections! @theamrhub
@unimelbMSPGH @SexHealthUoM
Read here: https://t.co/mGuICEhbBN

[Wintermute Biomedical Pty Ltd @WintermuteBio]

@fabian_kong @theamrhub @unimelbMSPGH @SexHealthUoM Likewise @fabian_kong! We're very excited to be working with you and your team.

[Wintermute Biomedical Pty Ltd @WintermuteBio]

Our antimicrobial #fattyacid technology is showing real promise for the prevention and treatment of a range of #infectiousdiseases.

The team, led by Thomas Rau and @_drfosh, has worked extremely hard this year to make this happen. Thank you for all your efforts!

[Wintermute Biomedical Pty Ltd @WintermuteBio]

It was great to share the progress we made in 2022 towards a #shingles #clinicalresearch program at our AGM today:
-Appointed a KOL
-Appointed a CRO
-Appointed a Trial Pathway Partner
-Developed key clinical assets & a clinical pathway plan
-Completed our 1st in-human skin study

[Wintermute Biomedical Pty Ltd @WintermuteBio]

@HelbigLab @ebony_monson @LTUresearchers @MAPP_latrobe @latrobe Congrats @ebony_monson!!

[Wintermute Biomedical Pty Ltd @WintermuteBio]

Our topical #therapy GS-1 has passed its first human safety test.

After repeated skin application in 100 subjects GS-1 ‘did not demonstrate a potential for eliciting dermal irritation or ... potential for inducing sensitization’.

An exciting milestone for our #shingles program.

[Wintermute Biomedical Pty Ltd @WintermuteBio]

We're so excited to see the latest application of our #fattyacid tech online!

Our spin-off company @TenCarbonChem shows that GS-2 is a powerful, broad-spectrum, & safe environmental #antimicrobial.

Congratulations to our team members @_drfosh & Tom Rau, & all involved! 👏👏

[Wintermute Biomedical Pty Ltd @WintermuteBio]

@AaronElbourne @SumeetWalia4 @eurekaprizes @ResearchRMIT Congratulations @SumeetWalia4! 👏👏

[Wintermute Biomedical Pty Ltd @WintermuteBio]

A true believer in our cause to provide safe and sustainable antimicrobials to the world, Carolyn is objectives driven, focused, and committed to obtaining the best outcomes for our clients and for the company.

We’re so fortunate to have you, Carolyn!

4/4

[Wintermute Biomedical Pty Ltd @WintermuteBio]

We’re delighted to introduce our superstar Operations Manager, Carolyn Riska.

1/4

[Wintermute Biomedical Pty Ltd @WintermuteBio]

After the acquisition of her company, Carolyn joined us in Q3 2021. Carolyn is capitalising on her experience by optimising our commercial pipelines to bring our best products to market & seeing our @TenCarbonChem customers receive superior products at cost-effective prices.

3/4

[Wintermute Biomedical Pty Ltd @WintermuteBio]

Looking for an exciting #PhD project working on novel environmental #antimicrobials?

Our spin-off company TCC is partnering with @ResearchRMIT to support a PhD project to do this.

Get the best of both academia and industry - a great way to kickstart your career in science.

[Wintermute Biomedical Pty Ltd @WintermuteBio]

@thezoeday @LIMSLTU Congrats Zoe! 👏

[Wintermute Biomedical Pty Ltd @WintermuteBio]

Link to the original article published in @IDSAInfo in May 2022👇

https://t.co/eDHncc6tGp

[Wintermute Biomedical Pty Ltd @WintermuteBio]

New Study: Adults age 50+ who had COVID-19 are 15% more likely to develop #Shingles within 6 months.

“This pain is significant—it’s excruciating pain—which there is really not a great treatment for."

The Shingles vaccine Shingrix is the best defense.

https://t.co/iMqpfL0P8l

[Wintermute Biomedical Pty Ltd @WintermuteBio]

@AaronElbourne @RACInational @ResearchRMIT @VizProd @rashad_kariuki @NanoIn3D Congrats Aaron, this is exciting stuff! Looking forward to seeing how our nanoparticles interact with membranes. You're clearly the right person for the job 👏

[Wintermute Biomedical Pty Ltd @WintermuteBio]

Tom is also leading the development of this technology for environmental & agricultural applications through our spin-off company Ten Carbon Chemistry.

On top of all this, Tom is an all-round great guy to work with.

We’re fortunate to be working with you, Tom.

4/4

[Wintermute Biomedical Pty Ltd @WintermuteBio]

We want you to get to know more of our amazing team!

Meet the Co-Founder & Chief Scientific Officer of Wintermute Biomedical, Dr. Tom Rau.

#CSO #Founder #Biotech

1/4

[Wintermute Biomedical Pty Ltd @WintermuteBio]

Since inventing a novel method for harnessing the antimicrobial power of fatty acids, Tom has been working tirelessly to use this method to develop new & effective therapies for #infectiousdiseases.

3/4